The company is indeed facing operational difficulties, said the Chairman of Chongqing Zhifei Biological Products: there are discrepancies in internal forecasts | Highlights from the Earnings Conference.

① Regarding the current predicament of the company, the Chairman of Chongqing Zhifei Biological Products, Jiang Rensheng, candidly stated during the Earnings Conference that internal responsibility factors are more significant, and management is reflecting deeply. ② The company stated that it is addressing the current difficulties by communicating with partners, reducing the procurement quantity of agency products, and strengthening collection assessments.

cls.cnMay 9 20:34

Core product revenue declines. Where will Guangxi Wuzhou Zhongheng Group's new profit growth points be?| Directly addressing the Earnings Conference.

① Due to the significant drop in price of the company's core product, thrombolytic injection, the performance of Guangxi Wuzhou Zhongheng Group continues to decline. ② The company's management indicated that in addition to internal growth, they will also achieve external expansion through mergers and acquisitions in the future, with a focus on the layout of Traditional Chinese Medicine, research and development, business development, and the supporting medical instruments sector.

cls.cnMay 7 23:55

Holiday reading | The "magic weight loss drug" market with a scale of hundreds of billions is entering a fierce competition stage.

Obesity, a health topic that modern people cannot avoid. As people sweat it out in the gym, feel anxious about numbers on the scale, and struggle repeatedly between dieting and indulging in food, "weight loss drugs" have also become the most profitable Gold avenue in the pharmaceutical industry.

PrismMay 4 14:23

In the first quarter, revenue declined year-on-year. Is Zhangzhou Pientzehuang Pharmaceutical's "An Gong" not selling well? | Interpretations

In the first quarter, Zhangzhou Pientzehuang Pharmaceutical's revenue was 3.142 billion yuan, a year-on-year decrease of 0.92%, marking a decline for two consecutive quarters. The Net income attributable to shareholders of the listed company was 1 billion yuan, an increase of 2.59% year-on-year. The sales of the company's Angong Niuhuang Pill, a representative medication for cardiovascular and cerebrovascular diseases, saw a decline of over 80%.

cls.cnApr 29 22:57

Zhangzhou Pientzehuang Pharmaceutical: First quarter performance is steady, with a significant increase in Cash / Money Market operating cash flow by 72.33%.

In the first quarter, Zhangzhou Pientzehuang Pharmaceutical's performance remained robust, with strong growth in operating cash flow highlighting key points of core competitiveness. Financial performance was stable: the first quarter achieved revenue of 3.142 billion yuan, a slight year-on-year decrease of 0.92%; net income attributable to the parent company was 0.9998 billion yuan, a year-on-year increase of 2.59%; and net profit excluding non-recurring items was 1.005 billion yuan, a year-on-year increase of 1.69%. Cash flow performance was impressive: the net cash flow from operating activities was 0.916 billion yuan, a significant year-on-year increase of 72.33%, mainly due to a reduction in expenditures on commodities. Cost control was notable: selling expenses decreased by 38.5% year-on-year to 1.013 billion yuan, while management and research & development expenses decreased respectively.

wallstreetcnApr 29 16:37

BOE Technology Group's Q1 performance saw double growth: Net income surged by 64%, and R&D investment continued to increase | Earnings Reports insights.

In the first quarter, BOE's revenue reached 50.6 billion yuan, a year-on-year increase of 10.27%. More significantly, the company's net income attributable to the parent reached 1.614 billion yuan, a substantial increase of 64.06% year-on-year, while the net income after deducting non-recurring gains and losses was 1.352 billion yuan, surging 126.56% year-on-year, indicating a significant improvement in the profitability of the company's core business.

wallstreetcnApr 29 04:28